Neoplasms

All Conditions

Symptoms and General Pathology

Mouth and Tooth Diseases

Nervous System Diseases

Wounds and Injuries

Adenoma

Facies

Facial Nerve Injuries

Adenoma, Pleomorphic

Disease Attributes

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Facial Nerve Diseases

Mouth Diseases

Stomatognathic Diseases

Cranial Nerve Injuries

Cranial Nerve Diseases

Craniocerebral Trauma

Trauma, Nervous System

All the patients with pleomorphic adenoma irrespective of age and gender who underwent Superficial parotidectomy

Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity

Superficial Parotidectomy

Fazila Hashmi, FCPS

In this single-centre, cross-sectional case series, the investigators aim to evaluate the incidence of facial nerve injury in patients undergoing superficial parotidectomy in the absence of nerve conductor. Data to be collected retrospectively from a prospectively maintained database of consecutive patients, at the Department of Surgery, Liaquat University of Medical and Health Sciences Jamshoro, Pakistan. The sample size was calculated as 101.

In this single-centre, cross-sectional case series, the investigators aim to evaluate the incidence of facial nerve injury in partcipants undergoing superficial parotidectomy in the absence of nerve conductor. The institutional Research Ethics Committee has approved the study. Data to be collected retrospectively from a prospectively maintained database, at the Department of Surgery, Liaquat University of Medical and Health Sciences Jamshoro, Pakistan. The data period to be over a period of nine years that is from 1st January 2012 till August 2020. The sample size was calculated using the WHO sample size calculator and taking disease prevalence as 7.1 with CI 95%, which turned out to be 101. All the patients with pleomorphic adenoma irrespective of age and gender were included. To control any chance of bias, one of the members of researchers as part of the team who operated upon these patients. The primary outcome was the incidence of temporary or permanent facial nerve injury, while secondary outcomes were wound infection, seroma, hematoma, Frey's syndrome, salivary fistula and disfigured scar. Temporary facial nerve injury was defined as a feature of facial nerve palsy with full recovery to regular activity within six months. Permanent facial nerve injury was defined as any facial nerve dysfunction lasting beyond six months of operation. The data was recorded on a predesigned Performa, and patients' confidentiality was maintained assigning codes to each case known only to researchers. The data was calculated using SPSS version 23. Values of mean and standard deviation were calculated for continuous variables, whereas frequencies were calculated for categorical data.

Facial Nerve Morbidity After Superficial Parotidectomy in the Absence of Nerve Conductor

Facial Nerve Morbidity After Superficial Parotidectomy in the Absence of Nerve Conductor: an Experience From a Low Resource Country

Temporary facial nerve injury was defined as a feature of facial nerve palsy with full recovery to regular activity within six months. Permanent facial nerve injury was defined as any facial nerve dysfunction lasting beyond six months of operation.

Rate of postoperative surgical site infection will be calculated

Rate of postoperative formation of seroma (non-infected collection) occurring after superficial parotidectomy will be calculated

Rate of postoperative incidence of hematoma/ clot formation at the operative site will be calculated

Frey's syndrome is the result of misdirected regeneration of parasympathetic fibres connecting with regenerating sympathetic nerve leading to facial sweating and flushing during times of eating food. Rate of occurrence of Frey's syndrome will be calculated to understand its incidence.

Salivary fistula is abnormal communication between skin and remaining gland. Its rate of occurrence will be calculated during postoperative period after superficial parotidectomy.

The number of participants developing cosmetically bad scar will be notified and data calculated.

Liaquat University of Medical & Health Sciences

Assistant Professor

Rare Diseases

Salivary Gland Neoplasms

Syringoma

Mouth Neoplasms

Head and Neck Neoplasms

Salivary Gland Diseases

Neoplasms, Adnexal and Skin Appendage

Oral Cancer

Antineoplastic Agents

All Drugs and Chemicals

Panitumumab

Antineoplastic Agents, Immunological

Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).

Radiation 64-70Gy (2.0 Gy/day, 5 days/week)

Radiation

2.5 mg/Kg IV, weekly during RT. 6-7 weeks

Michael K. Gibson, MD

Standard therapy for high-risk or locally advanced salivary gland malignancies is surgery followed by postoperative radiation therapy. Retrospective studies have shown the superiority of combined modality therapy compared to surgery alone for patients with advanced T or N stage. Despite the addition of postoperative radiation therapy, the five-year survival for locally advanced salivary gland malignancies is poor (less than 60%). In salivary gland malignancies, the epidermal growth factor receptor (EGFR) is expressed in 25-85%; in certain histological types, like salivary duct carcinomas, the expression is higher. EGFR is a promising target of anticancer therapy. In squamous cell carcinoma of the head and neck, a phase III trial utilizing cetuximab added to radiation therapy improved both locoregional control and overall survival compared to radiation alone. Panitumumab is a novel, human, IgG2 EGFR monoclonal antibody that may be better tolerated and more efficacious than cetuximab. Here, the investigators suggest that the addition of panitumumab to standard radiotherapy in locally-advanced salivary gland malignancies will improve recurrence-free survival (RFS).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Facial Nerve Morbidity After Superficial Parotidectomy in the Absence of Nerve Conductor	NCT04706052	Facial Nerve In... Adenoma, Pleomo...	Superficial Par...	-	Liaquat University of Medical & Health Sciences
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies	NCT00984217	Adenoma, Pleomo... Mixed Salivary ... Salivary Gland ... Syringoma, Chon...	Radiation Panitumumab	18 Years -	University of Pittsburgh

Spots Global Cancer Trial Database for adenoma, pleomorphic